natgillin/translations-raw huggingface dataset:
mean and associated error term (e.g. SD, SEM) for BrdU labelling index/mouse for each treatment group and the results of outlier analysis for each treatment group;
iga katserühma BrdU-märgistusindeksi/hiire keskväärtus ja selle viga (näiteks standardhälve, standardviga) ning iga katserühma võõrväärtuste analüüsi tulemused;
NIH Publication No 10-7552A/B.
10-7552 A/B.
Available at: [http://iccvam.niehs.nih.gov/methods/immunotox/llna-ELISA/TMER.htm]
Vt: http://iccvam.niehs.nih.gov/methods/immunotox/llna-ELISA/TMER.htm
Available at: [http://iccvam.niehs.nih.gov/docs/immunotox_docs/LLNAPRPRept2009.pdf]
Vt: http://iccvam.niehs.nih.gov/docs/immunotox_docs/LLNAPRPRept2009.pdf
Available at: [http://iccvam.niehs.nih.gov/methods/acutetox/Tox_workshop.htm].
Vt: http://iccvam.niehs.nih.gov/methods/acutetox/Tox_workshop.htm.
OECD (2005), Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment, Environment, Health and Safety Monograph Series on Testing and Assessment No 34, ENV/JM/MONO(2005)14, OECD, Paris.
OECD (2005), Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment, Environment, Health and Safety Monograph Series on Testing and Assessment No. 34, ENV/JM/MONO(2005)14, OECD, Paris.
The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method (33).
Seda terminit kasutatakse ka vastavuse tähenduses ja see näitab, kui sageli annab katsemeetod õige tulemuse (33).
A benchmark substance should have the following properties: (i) a consistent and reliable source(s); (ii) structural and functional similarity to the class of substances being tested; (iii) known physical/chemical characteristics; (iv) supporting data on known effects; and (v) known potency in the range of the desired response.
Võrdlusainel peaksid olema järgmised omadused: i) pidev ja usaldusväärne tarnija; ii) struktuuriline ja funktsionaalne sarnasus uuritava ainega; iii) teadaolevad füüsikalised ja keemilised omadused; iv) täiendavad andmed teadaolevate mõjude kohta ja v) teadaolev mõjusus soovitavas mõju tugevuse vahemikus.
False negative A test substance incorrectly identified as negative or non-active by a test method, when in fact it is positive or active (33).
Valenegatiiv uuritav aine, mis on katsemeetodiga ekslikult tunnistatud negatiivseks või toimetuks, kui see tegelikult on positiivne või sensibiliseeriva toimega (33).
False positive A test substance incorrectly identified as positive or active by a test, when in fact it is negative or non-active (33).
Valepositiiv uuritav aine, mis on katsemeetodiga ekslikult tunnistatud positiivseks või sensibiliseerivat toimet omavaks, kui see tegelikult on negatiivne või sensibiliseeriva toimeta (33).
Inter-laboratory reproducibility A measure of the extent to which different qualified laboratories, using the same protocol and testing the same test substance, can produce qualitatively and quantitatively similar results.
Laboritevaheline reprodutseeritavus suurus, mis näitab, millisel määral suudavad erinevad kvalifitseeritud laborid, kasutades sama katse-eeskirja ja uurides sama ainet, saada kvalitatiivselt ja kvantitatiivselt sarnaseid tulemusi.
It is assessed by calculating intra- and inter-laboratory reproducibility (33).
Usaldusväärsuse hindamiseks arvutatakse laborisisene ja laboritevaheline reprodutseeritavus (33).
These Reference Chemicals are a subset of the Reference Chemicals used in the validation study.
Tabelis esitatud võrdluskemikaalid on osa valideerimisuuringus kasutatud võrdluskemikaalidest.
In vivo score in accordance with B.4 and OECD Test Guideline 404 (4).
Hinne in vivo, vastavalt B.4-le ja OECD katsejuhendile 404 (4).
Under this Test Method, the UN GHS optional Category 3 (mild irritants) (1) is considered as No Category.
Käesoleva katsemeetodi kohaselt käsitatakse ÜRO GHS-süsteemi 3. valikkategooriat (nõrgad ärritajad) (1) kategooria puudumisena (kategooriata).
The UN GHS optional Category3 is not applicable under the EU CLP.
ÜRO GHS-süsteemi 3. valikkategooria ei ole ELi CLP-määruse järgi kohaldatav.
Toxicol., 30, 165-169.
Toxicol., 30, 165–169.
, The local lymph node assay: developments and applications, Toxicol., 93, 13-31.
, The local lymph node assay: developments and applications, Toxicol., 93, 13–31.
Health, 53, 563-79.
Health, 53, 563–79.
Toxicol., 34, 985-997.
Toxicol., 34, 985–997.
Toxicol., 36, 327-33.
Toxicol., 36, 327–33.
Van Och, F.M.M., Slob, W., De Jong, W.H., Vandebriel, R.J. and Van Loveren, H. (2000), A quantitative method for assessing the sensitising potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of uncertainty margins, Toxicol., 146, 49-59.
Van Och, F.M.M., Slob, W., De Jong, W.H., Vandebriel, R.J. and Van Loveren, H. (2000), A quantitative method for assessing the sensitising potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of uncertainty margins, Toxicol., 146, 49–59.
Pharmacol, 34: 258-273.
Pharmacol, 34: 258–273.
Pharmacol, 34, 274-286.
Pharmacol, 34, 274–286.
Pharmacol, 34: 249-257.
Pharmacol, 34: 249–257.
Toxicol., 18, 281-284.
Toxicol., 18, 281–284.
Contact Dermatitis, 54, 181-185.
Contact Dermatitis, 54, 181–185.
Toxicol., 46, 1896-1904.
Toxicol., 46, 1896–1904.
Pharmacol., 55, 90-96.
Pharmacol., 55, 90–96.
, The murine local lymph node assay: regulatory and potency considerations under REACH, Toxicol., 238, 71-89.
, The murine local lymph node assay: regulatory and potency considerations under REACH, Toxicol., 238, 71–89.
OECD (2002), Acute Dermal Irritation/Corrosion.
OECD (2002), Acute Dermal Irritation/Corrosion. OECD Guideline for Testing of Chemicals No.
Toxicol., 21, 195-206.
Toxicol., 21, 195–206.
Pharmacol., 153, 83-94.
Pharmacol., 153, 83–94.
Meth., 8, 245-256.
Meth., 8, 245–256.
Toxicol., 22, 491-506.
Toxicol., 22, 491–506.
Toxicol., 212, 60-68.
Toxicol., 212, 60–68.
Toxicol., 79, 721-728.
Toxicol., 79, 721–728.
Complete supporting information for the specific RhE model used including its performance.
kogu täiendav teave kasutatud konkreetse RhE-mudeli ja selle tulemuslikkuse kohta.
This should include, but is not limited to;
See hõlmab vähemalt järgmist:
Reference to historical data of the model.
viide varasematele andmetele mudeli kohta.
EC-ECVAM (2009), Statement on the “Performance under UN GHS of three in vitro assays for skin irritation testing and the adaptation of the Reference Chemicals and Defined Accuracy Values of the ECVAM skin irritation Performance Standards”, issued by the ECVAM Scientific Advisory Committee (ESAC30), 9 April 2009.
EC-ECVAM (2009), Statement on the „Performance under UN GHS of three in vitro assays for skin irritation testing and the adaptation of the Reference Chemicals and Defined Accuracy Values of the ECVAM skin irritation Performance Standards”, issued by the ECVAM Scientific Advisory Committee (ESAC30), 9 April 2009.
M. and Botham, P. (2001), A prevalidation study on in vitro tests for acute skin irritation, Results and evaluation by the Management Team, Toxicol. in Vitro 15, 57-93.
M. and Botham, P. (2001), A prevalidation study on in vitro tests for acute skin irritation, Results and evaluation by the Management Team, Toxicol. in Vitro 15, 57–93.
Cotovio, J., Grandidier, M.-H., Portes, P., Roguet, R. and Rubinsteen, G. (2005), The in vitro acute skin irritation of chemicals: optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process, ATLA 33, 329-349.
Cotovio, J., Grandidier, M.-H., Portes, P., Roguet, R. and Rubinsteen, G. (2005), The in vitro acute skin irritation of chemicals: optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process, ATLA 33, 329–349.
Zuang, V., Balls, M., Botham, P.A., Coquette, A., Corsini, E., Curren, R.D., Elliot, G.R., Fentem, J.H., Heylings, J.R., Liebsch, M., Medina, J., Roguet, R., van De Sandt, J.J.M., Wiemann, C. and Worth, A. (2002), Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation, The European Centre for the Validation of Alternative Methods Skin Irritation Task Force report 2, ATLA 30, 109-129.
Zuang, V., Balls, M., Botham, P.A., Coquette, A., Corsini, E., Curren, R.D., Elliot, G.R., Fentem, J.H., Heylings, J.R., Liebsch, M., Medina, J., Roguet, R., van De Sandt, J.J.M., Wiemann, C. and Worth, A. (2002), Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation, The European Centre for the Validation of Alternative Methods Skin Irritation Task Force report 2, ATLA 30, 109–129.
Spielmann, H., mailto:Hoffmann, S., Liebsch, M., Botham, P., Fentem, J., Eskes, C., Roguet, R., Cotovio, J., Cole, T., Worth, A., Heylings, J., Jones, P., Robles, C., Kandárová, H., mailto:Gamer, A., Remmele, M., Curren, R., Raabe, H., Cockshott, A., Gerner, I. and Zuang, V. (2007), The ECVAM international validation study on in vitro tests for acute skin irritation: Report on the validity of the EPISKIN and EpiDerm assays and on the skin integrity function test, ATLA 35, 559-601.
Spielmann, H., mailto:Hoffmann, S., Liebsch, M., Botham, P., Fentem, J., Eskes, C., Roguet, R., Cotovio, J., Cole, T., Worth, A., Heylings, J., Jones, P., Robles, C., Kandárová, H., mailto:Gamer, A., Remmele, M., Curren, R., Raabe, H., Cockshott, A., Gerner, I. and Zuang, V. (2007), The ECVAM international validation study on in vitro tests for acute skin irritation: Report on the validity of the EPISKIN and EpiDerm assays and on the skin integrity function test, ATLA 35, 559–601.
Eskes, C., Cole, T., Hoffmann, S., Worth, A., Cockshott, A., Gerner, I. and Zuang, V. (2007), The ECVAM international validation study on in vitro tests for acute skin irritation: selection of test chemicals, ATLA 35, 603-619.
Eskes, C., Cole, T., Hoffmann, S., Worth, A., Cockshott, A., Gerner, I. and Zuang, V. (2007), The ECVAM international validation study on in vitro tests for acute skin irritation: selection of test chemicals, ATLA 35, 603–619.
OECD (2010), Explanatory background document to the OECD draft Test Guideline on in vitro skin irritation testing.
OECD (2010), Explanatory background document to the OECD draft Test Guideline on in vitro skin irritation testing. OECD Series on Testing and Assessment, No.
State of the art review of mechanisms and models, Toxicol. in Vitro 18, 231-243.
State of the art review of mechanisms and models, Toxicol. in Vitro 18, 231–243.
Methods 65, 55-63.
Methods 65, 55–63.
Contact Dermatitis 51, 1-4.
Contact Dermatitis 51, 1–4.
Jirova, D., Liebsch, M., Basketter, D., Spiller, E., Kejlova, K., Bendova, H., Marriott, M. and Kandarova, H. (2007), Comparison of human skin irritation and photo-irritation patch test data with cellular in vitro assays and animal in vivo data, ALTEX, 14, 359-365.
Jirova, D., Liebsch, M., Basketter, D., Spiller, E., Kejlova, K., Bendova, H., Marriott, M. and Kandarova, H. (2007), Comparison of human skin irritation and photo-irritation patch test data with cellular in vitro assays and animalin vivo data, ALTEX, 14, 359–365.
Jírová, D., Basketter, D., Liebsch, M., Bendová, H., Kejlová, K., Marriott, M. and Kandárová, H. (2010), Comparison of human skin irritation patch test data with in vitro skin irritation assays and animal data, Contact Dermatitis, 62, 109-116.
Jírová, D., Basketter, D., Liebsch, M., Bendová, H., Kejlová, K., Marriott, M. and Kandárová, H. (2010), Comparison of human skin irritation patch test data with in vitro skin irritation assays and animal data, Contact Dermatitis, 62, 109–116.
In addition to using the MNvit assay to identify chemicals (substances and mixtures) that induce micronuclei, the use of a cytokinesis block, immunochemical labelling of kinetochores, or hybridisation with centromeric/telomeric probes (fluorescence in situ hybridisation (FISH)), also can provide information on the mechanisms of chromosome damage and micronucleus formation (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16).
Lisaks MNvit-katse kasutamisele mikrotuumi tekitavate kemikaalide (ainete või segude) kindlakstegemiseks võib teavet kromosoomikahjustuste ja mikrotuumade tekkimise kohta saada veel tsütokineesibloki, kinetokooride immunokeemilise märgistamisega või tsentromeeri-/telomeerisondidega hübridiseerimisega (fluorestents in situ hübridisatsiooniga (FISH)) kasutamisega (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16).
The labelling and hybridisation procedures can be used when there is an increase in micronucleus formation and the investigator wishes to determine if the increase was the result of clastogenic and/or aneugenic events.
Märgistamist ja hübridiseerimist võib kasutada, kui on tekkinud rohkesti mikrotuumi ja uurija tahab kindlaks teha, kas nende tekkimise põhjuseks on klastogeenne ja/või aneugeenne protsess.
The use of a DNA specific stain (e.g. acridine orange (61) or Hoechst 33258 plus pyronin-Y (62)) can eliminate some of the artefacts associated with using a non-DNA specific stain.
DNA-spetsiifilise värvaine kasutamine (nt akridiinoranž (61) või Hoechst 33258 + püroniin-Y (62)) võib kõrvaldada mõne muude kui DNA-spetsiifiliste värvainete kasutamisega seotud artefakti.
Anti-kinetochore antibodies, FISH with pancentromeric DNA probes, or primed in situ labelling with pancentromere-specific primers, together with appropriate DNA counterstaining, can be used to identify the contents (chromosome/chromosomal fragment) of micronuclei if mechanistic information of their formation is of interest (15) (16).
Kui soovitakse saada teavet mikrotuumade moodustumise mehhanismi kohta, võib mikrotuumade sisalduse (kromosoom/kromosoomifragment) kindlakstegemiseks kasutada kinetokoorivastaseid antikehi, fluorestentsi in situ hübridisatsiooniga (FISH) pantsentromeersete DNA-sondidega või praimitud in situ märgistamist pantsentromeerispetsiifilise praimeriga koos DNA sobiva vastandvärvimisega.
Other methods for differentiation between clastogens and aneugens may be used if they have been shown to be effective.
Klastogeenide ja aneugeenide eristamiseks võib kasutada muid meetodeid, mille kohta on tõendatud, et need on tõhusad.
Mutation Res., 392, 1-4.
Mutation Res., 392, 1–4.
Parry, J.M. and Sors, A. (1993), The detection and assessment of the aneugenic potential of environmental chemicals: the European Community aneuploidy project, Mutation Res., 287, 3-15.
Parry, J.M. and Sors, A. (1993), The detection and assessment of the aneugenic potential of environmental chemicals: the European Community aneuploidy project, Mutation Res., 287, 3–15.
, Solutions to the kinetic problem in the micronucleus assay, Cytobios., 43, 233-246.
, Solutions to the kinetic problem in the micronucleus assay, Cytobios., 43, 233–246.
Mutagen., 35, 167-172.
Mutagen., 35, 167–172.
Fenech, M. (2007), Cytokinesis-block micronucleus cytome assay, Nature Protocols, 2(5), 1084-1104.
Fenech, M. (2007), Cytokinesis-block micronucleus cytome assay, Nature Protocols, 2(5), 1084-1104.
, Cytokinesis-block micronucleus method in human lymphocytes: effect of in-vivo ageing and low dose X-irradiation, Mutation Res., 161, 193-198.
, Cytokinesis-block micronucleus method in human lymphocytes: effect of in-vivo ageing and low dose X-irradiation, Mutation Res., 161, 193–198.
Mutagen., 13, 34-43.
Mutagen., 13, 34–43.
Eastmond, D.A. and Pinkel, D. (1990), Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in-situ hybridisation with chromosome-specific DNA probes, Mutation Res., 234, 9-20.
Eastmond, D.A. and Pinkel, D. (1990), Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in-situ hybridisation with chromosome-specific DNA probes, Mutation Res., 234, 9–20.
, Classification of micronuclei in murine erythrocytes: immunofluorescent staining using CREST antibodies compared to in situ hybridization with biotinylated gamma satellite DNA, Mutagenesis, 6, 297-302.
, Classification of micronuclei in murine erythrocytes: immunofluorescent staining using CREST antibodies compared to in situ hybridization with biotinylated gamma satellite DNA, Mutagenesis, 6, 297–302.
, The use of fluorescence in-situ hybridisation for the detection of aneugens in cytokinesis-blocked mouse splenocytes, Mutagenesis, 8, 329-334.
, The use of fluorescence in-situ hybridisation for the detection of aneugens in cytokinesis-blocked mouse splenocytes, Mutagenesis, 8, 329–334.
Migliore, L., Bocciardi, R., Macri, C. and Lo Jacono, F. (1993), Cytogenetic damage induced in human lymphocytes by four vanadium compounds and micronucleus analysis by fluorescence in situ hybridization with a centromeric probe, Mutation Res., 319, 205-213.
Migliore, L., Bocciardi, R., Macri, C. and Lo Jacono, F. (1993), Cytogenetic damage induced in human lymphocytes by four vanadium compounds and micronucleus analysis by fluorescence in situ hybridization with a centromeric probe, Mutation Res., 319, 205–213.
Norppa, H., Renzi, L. and Lindholm, C. (1993), Detection of whole chromosomes in micronuclei of cytokinesis-blocked human lymphocytes by antikinetochore staining and in situ hybridization, Mutagenesis, 8, 519-525.
Norppa, H., Renzi, L. and Lindholm, C. (1993), Detection of whole chromosomes in micronuclei of cytokinesis-blocked human lymphocytes by antikinetochore staining and in situ hybridization, Mutagenesis, 8, 519–525.
, Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes, Mutation Res., 322, 9-20.
, Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes, Mutation Res., 322, 9–20.
, Fluorescence in situ hybridisation (FISH) with chromosome-specific centromeric probes: a sensitive method to detect aneuploidy, Mutation Res., 372, 233-245.
, Fluorescence in situ hybridisation (FISH) with chromosome-specific centromeric probes: a sensitive method to detect aneuploidy, Mutation Res., 372, 233–245.
Zijno, P., Leopardi, F., Marcon, R. and Crebelli, R. (1996), Analysis of chromosome segregation by means of fluorescence in situ hybridization: application to cytokinesis-blocked human lymphocytes, Mutation Res., 372, 211-219.
Zijno, P., Leopardi, F., Marcon, R. and Crebelli, R. (1996), Analysis of chromosome segregation by means of fluorescence in situ hybridization: application to cytokinesis-blocked human lymphocytes, Mutation Res., 372, 211–219.
Mutation Res., 540, 153-163.
Mutation Res., 540, 153–163.
I. General conditions and overall conclusions of the study, Mutation Res., 607, 13-36.
I. General conditions and overall conclusions of the study, Mutation Res., 607, 13–36.
Using human lymphocytes, Mutation Res., 607, 37-60.
Using human lymphocytes, Mutation Res., 607, 37–60.
Using CHO cells, Mutation Res., 607, 61-87.
Using CHO cells, Mutation Res., 607, 61–87.
Using CHO/IU cells, Mutation Res., 607, 88-124.
Using CHO/IU cells, Mutation Res., 607, 88–124.
Oliver, J., Meunier, J.-R., Awogi, T., Elhajouji, A., Ouldelhkim, M.-C., Bichet, N., Thybaud, V., Lorenzon, G., Marzin, D. and Lorge, E. (2006), SFTG International collaborative study on the in vitro micronucleus test, V. Using L5178Y cells, Mutation Res., 607, 125-152.
Oliver, J., Meunier, J.-R., Awogi, T., Elhajouji, A., Ouldelhkim, M.-C., Bichet, N., Thybaud, V., Lorenzon, G., Marzin, D. and Lorge, E. (2006), SFTG International collaborative study on the in vitro micronucleus test, V. Using L5178Y cells, Mutation Res., 607, 125–152.
Albertini, S., Miller, B., Chetelat, A.A. and Locher, F. (1997), Detailed data on in vitro MNT and in vitro CA: industrial experience, Mutation Res., 392, 187-208.
Albertini, S., Miller, B., Chetelat, A.A. and Locher, F. (1997), Detailed data on in vitro MNT and in vitro CA: industrial experience, Mutation Res., 392, 187–208.
Miller, B., Albertini, S., Locher, F., Thybaud, V. and Lorge, E. (1997), Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: industrial experience, Mutation Res., 392, 45-59.
Miller, B., Albertini, S., Locher, F., Thybaud, V. and Lorge, E. (1997), Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: industrial experience, Mutation Res., 392, 45–59.
Gesellschaft fur Umwelt-Mutations-forschung, Mutation Res., 410, 81-116.
Gesellschaft fur Umwelt-Mutations-forschung, Mutation Res., 410, 81–116.
Kersten, B., Zhang, J., Brendler Schwaab, S.Y., Kasper, P. and Müller, L. (1999), The application of the micronucleus test in Chinese hamster V79 cells to detect drug-induced photogenotoxicity, Mutation Res. 445, 55-71.
Kersten, B., Zhang, J., Brendler Schwaab, S.Y., Kasper, P. and Müller, L. (1999), The application of the micronucleus test in Chinese hamster V79 cells to detect drug-induced photogenotoxicity, Mutation Res. 445, 55–71.
, A protocol for the in vitro micronucleus test, I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity, Mutation Res., 517, 123-134.
, A protocol for the in vitro micronucleus test, I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity, Mutation Res., 517, 123–134.
Matsushima, T., Hayashi, M., Matsuoka, A., Ishidate, M. Jr., Miura, K.F., Shimizu, H., Suzuki, Y., Morimoto, K., Ogura, H., Mure, K., Koshi, K. and Sofuni, T. (1999), Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU), Mutagenesis, 14, 569-580.
Matsushima, T., Hayashi, M., Matsuoka, A., Ishidate, M. Jr., Miura, K.F., Shimizu, H., Suzuki, Y., Morimoto, K., Ogura, H., Mure, K., Koshi, K. and Sofuni, T. (1999), Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU), Mutagenesis, 14, 569–580.
Elhajouji, A., and Lorge, E. (2006), Special Issue: SFTG International collaborative study on in vitro micronucleus test, Mutation Res., 607, 1-152.
Elhajouji, A., and Lorge, E. (2006), Special Issue: SFTG International collaborative study on in vitro micronucleus test, Mutation Res., 607, 1–152.
Corvi, R., Albertini, S., Hartung, T., Hoffmann, S., Maurici, D., Pfuhler, S, van Benthem, J., Vanparys P. (2008), ECVAM Retrospective Validation of in vitro Micronucleus Test (MNT), Mutagenesis, 23, 271-283.
Corvi, R., Albertini, S., Hartung, T., Hoffmann, S., Maurici, D., Pfuhler, S, van Benthem, J., Vanparys P. (2008), ECVAM Retrospective Validation of in vitro Micronucleus Test (MNT), Mutagenesis, 23, 271–283.
Zhang, L.S., Honma, M., Hayashi, M., Suzuki, T., Matsuoka, A. and Sofuni, T. (1995), A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test, Mutation Res., 347, 105-115.
Zhang, L.S., Honma, M., Hayashi, M., Suzuki, T., Matsuoka, A. and Sofuni, T. (1995), A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test, Mutation Res., 347, 105–115.
Ehrlich, V., Darroudi, F., Uhl, M., Steinkellner, S., Zsivkovits, M. and Knasmeuller, S. (2002), Fumonisin B1 is genotoxic in human derived hepatoma (HepG2) cells, Mutagenesis, 17, 257-260.
Ehrlich, V., Darroudi, F., Uhl, M., Steinkellner, S., Zsivkovits, M. and Knasmeuller, S. (2002), Fumonisin B1 is genotoxic in human derived hepatoma (HepG2) cells, Mutagenesis, 17, 257–260.
, Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge, Toxicol., 198, 315-328.
, Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge, Toxicol., 198, 315–328.